News

News 21.06.2018 Zurich-Schlieren, June 21, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today the appointment of Pamela A. Trail, Ph.D., as Chief Scientific Officer. Pamela Trail served most recently as Vice President of Oncology Strategy and Program Direction...

News 19.06.2018 Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15thannual State of Spine Surgery Think Tank, a leading conference uniquely dedicated to innovation in spinal surgery. The case studies, in which MagnetOs Granules were implanted in the spine, were performed by Alwyn...

News 15.06.2018 Zurich-Schlieren, June 15, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, announced today that the company will present updated preliminary results from the ongoing Phase 2 study of its lead proprietary oncology drug MP0250 at the 23th Annual...

News 13.06.2018 Schlieren, Switzerland – June 13, 2018 InSphero AG today announced that it has raised USD 10 million in its latest funding round with additional financing, secured from internal and external investors, bringing its total funding to date to USD 35 million. An innovative provider of 3D cellbased platforms for drug discovery and efficacy...

News 12.06.2018 Study should further enhance competitive positioning of MagnetOs Kuros announced that the University Medical Center Utrecht (UMCU) in the Netherlands has obtained approval from its ethical committee to start an investigator-led multicenter study comparing MagnetOs with autologous bone in posterolateral spinal fusion. The study is entitled "A Randomized Controlled Trial of MagnetOs®...